1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,400 | 1,480 | 17:04 | |
| 1,410 | 1,490 | 17:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive | 362 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Steve... ► Artikel lesen | |
| Mo | NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 | 429 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the... ► Artikel lesen | |
| 22.10. | In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides | 451 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong... ► Artikel lesen | |
| 20.10. | A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus | 453 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong... ► Artikel lesen | |
| 15.10. | NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses | 413 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains... ► Artikel lesen | |
| 01.10. | NanoViricides verlängert Verträge mit Führungskräften und passt Kreditlinie an | 3 | Investing.com Deutsch | ||
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 01.10. | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 30.09. | NanoViricides, Inc. Has Filed its Annual Report | 629 | ACCESS Newswire | Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections SHELTON, CONNECTICUT / ACCESS Newswire / September 30... ► Artikel lesen | |
| 29.09. | NANOVIRICIDES, INC. - 10-K, Annual Report | 9 | SEC Filings | ||
| 09.09. | NanoViricides to Present at the Life Science Executive Partnering Congress in Boston on September 17, 2025 | 772 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 18.08. | NanoViricides: A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials | 548 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 30.07. | Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides | 849 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 23.07. | NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value | 835 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 21.07. | Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides | 896 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 16.07. | WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides | 872 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 14.07. | Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides | 963 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 01.07. | NanoViricides: There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate | 748 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 18.06. | With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan | 726 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), asserts that with new rising variants of COVID and Bird Flu, the... ► Artikel lesen | |
| 04.06. | NanoViricides Measles Drug Development Animal Study is Imminent | 795 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 28.05. | NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 | 1.142 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 22,100 | -1,34 % | EQS-News: Formycon AG: Formycon lädt zur Telefonkonferenz zum Neunmonatsergebnis 2025 ein und gibt Teilnahme an Investorenkonferenzen im 4. Quartal 2025 bekannt | EQS-News: Formycon AG
/ Schlagwort(e): Sonstiges
Formycon lädt zur Telefonkonferenz zum Neunmonatsergebnis 2025 ein und gibt Teilnahme an Investorenkonferenzen im 4. Quartal 2025... ► Artikel lesen | |
| GOMSPACE | 1,614 | +2,15 % | GomSpace Group AB: GomSpace announces upgraded 2025 outlook with substantial revenue growth and strong EBITDA margin | GomSpace increases its revenue outlook by more than 100 M.SEK and confirms a strong positive EBITDA margin.
Revenue: 420 to 450 M.SEK (320 to 380 M.SEK)
EBITDA margin: 6% to 12% (-2% to +10%)
EBITDA... ► Artikel lesen | |
| KOPIN | 2,950 | -2,96 % | Kopin Corporation Announces Agreement for $15 Million Strategic Investment From Theon International Plc to Accelerate Global Defense Innovation | Kopin gains significant access to the European and NATO defense market
Accelerates development of critical technologies
Further strengthens Kopin's balance sheet
Fixed conversion... ► Artikel lesen | |
| ONTO INNOVATION | 118,00 | -0,84 % | Onto Innovation stock price target raised by Oppenheimer to $180 | ||
| XTPL | 17,840 | +5,56 % | EQS-News: XTPL S.A.: XTPL reports the strongest Q3 in its history, with commercial sales exceeding PLN 10.2 million in the first nine months of 2025 | Issuer: XTPL S.A.
/ Key word(s): Preliminary Results/9 Month figures
XTPL reports the strongest Q3 in its history, with commercial sales exceeding PLN 10.2 million in the first... ► Artikel lesen | |
| SOLESENCE | 3,500 | -3,58 % | Solésence, Inc.: Solésence Reports Second Quarter 2025 Financial Results | ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced... ► Artikel lesen | |
| GAUZY | 5,850 | 0,00 % | Gauzy Ltd. Announces Second Quarter 2025 Results | Record Backlog Purchase Orders of $42.9 Million at Quarter End Highly Anticipated New Product Lines Announced; Includes Commercial Aircraft Cabin Shading, ADAS Smart Vision for Buses, and Pre-Fabricated... ► Artikel lesen | |
| DOTZ NANO | 0,032 | +5,00 % | DOTZ NANO LIMITED: Application for quotation of securities - DTZ | ||
| NANOFOCUS | 1,760 | -4,85 % | Nanofocus: Abfindungsangebot klar über aktuellem Kurs | Seit Ende Mai ist bekannt, dass die Carl Mahr Holding Nanofocus übernehmen will. Jetzt wird die Sache sehr konkret. Die Gesellschaft aus Göttingen legt ein konkretisiertes Squeeze-Out-Verlangen vor.... ► Artikel lesen | |
| FENDX TECHNOLOGIES | 0,360 | -10,89 % | FendX Technologies Inc.: FendX Files Provisional Patent for Novel Antimicrobial Nanoparticle Liquid Coating | Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company... ► Artikel lesen | |
| OBDUCAT | 0,038 | -2,56 % | NGM MARKET NOTICE: #25-43 Information regarding the last day of trading in paid subscribed shares issued by Obducat AB | ||
| ACACIA RESEARCH | 2,880 | 0,00 % | Acacia Research und Partner entwickeln eine mit Bitcoin gesicherte Gewerbedarlehensstrategie | ||
| ADVANCE ZINCTEK | 0,600 | 0,00 % | ADVANCE ZINCTEK LIMITED: Notice of Annual General Meeting/Proxy Form | ||
| LAMPETIA | 0,102 | 0,00 % | EQS-News: Lampetia AG: Halbjahresfinanzbericht auf neuer Webseite | EQS-News: Lampetia AG
/ Schlagwort(e): Halbjahresbericht
LAMPETIA AG: Halbjahresfinanzbericht auf neuer Webseite
30.09.2025 / 19:51 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| RIBER | 3,250 | +2,52 % | 2025 first-half earnings: RIBER confirms the rollout of its roadmap and its annual outlook | 2025 first-half earnings: RIBER confirms the rollout of its roadmap and its annual outlook. Half-year revenues and earnings, particularly marked by seasonal activity patterns. Order book of €27.7m... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Die relative Kursveränderung beträgt aktuell +2,53 % bei einem Aktienkurs von 1,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.